Polycythemia vera in pregnancy represents a challenge for a multidisciplinary collaboration: A case report and literature review

Bohiltea,Roxana Elena; Niculescu‑Mizil,Emilia; Mihai,Bianca Margareta; Furtunescu,Florentina; Ducu,Ionita; Munteanu,Octavian; Georgescu,Tiberiu Augustin; Grigoriu,Corina

doi:10.3892/etm.2021.10941

January-2022 Volume 23 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2022 Volume 23 Issue 1

Full Size Image

Case Report

Polycythemia vera in pregnancy represents a challenge for a multidisciplinary collaboration: A case report and literature review

Authors:
- Roxana Elena Bohiltea
- Emilia Niculescu‑Mizil
- Bianca Margareta Mihai
- Florentina Furtunescu
- Ionita Ducu
- Octavian Munteanu
- Tiberiu Augustin Georgescu
- Corina Grigoriu
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania, Department of Hematology, ‘Provita’ Medical Center, 011442 Bucharest, Romania, Department of Obstetrics and Gynecology, University Emergency Hospital Bucharest, 050098 Bucharest, Romania, Department of Public Health and Management, Faculty of Medicine, ‘Carol Davila’ University of Medicine and Pharmacy, 050463 Bucharest, Romania, Department of Pathology, Faculty of Medicine, ‘Carol Davila’ University of Medicine and Pharmacy, 050463 Bucharest, Romania
Article Number: 19
|
Published online on: November 1, 2021

https://doi.org/10.3892/etm.2021.10941
Expand metrics +

Abstract

Polycythemia vera (PV) is a rare chronic myeloproliferative neoplasm which represents an additional thrombotic factor in pregnancy. PV may be difficult to diagnose, particularly as its incidence is extremely uncommon among young women. The main diagnostic method involves a bone marrow biopsy, and high hemoglobin and platelet counts are usually indicative of the condition, after excluding other more frequent pathologies. PV is associated with a high risk of thrombosis, particularly in pregnancy, and requires anti‑platelet treatment. At present, only a limited number of PV cases in pregnancy have been reported in the literature, at least to the best of our knowledge, with the largest case series being a retrospective study that included 25 pregnancies in 15 women. The present study describes the case of a patient diagnosed with JAK2‑positive PV and also discusses this rare condition with particular focus on the following: i) The management of PV in pregnancy along with the additional pathologies in this specific case; and ii) the particularities of the pregnancy course. By identifying women suffering from PV superimposed by other possible procoagulant factors and applying the latest standard in healthcare, fetal and maternal prognosis may be significantly improved.

View Figures

View References

1	Stuart BJ and Viera AJ: Polycythemia vera. Am Fam Physician. 69:2139–2144. 2004.PubMed/NCBI
2	Robinson S, Bewley S, Hunt BJ, Radia DH and Harrison CN: The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica. 90:1477–1483. 2005.PubMed/NCBI
3	Passamonti F, Malabarba L, Orlandi E, BaratèC Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C and Lazzarino M: Polycythemia vera in young patients: A study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 88:13–18. 2003.PubMed/NCBI
4	Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R and Larocca LM: Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol. 25:1048–1053. 2007.PubMed/NCBI View Article : Google Scholar
5	Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, et al: Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia. 27:1874–1881. 2013.PubMed/NCBI View Article : Google Scholar
6	Anía BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN and Melton LJ III: Trends in the incidence of polycythemia vera among olmsted county, Minnesota residents, 1935-1989. Am J Hematol. 47:89–93. 1994.PubMed/NCBI View Article : Google Scholar
7	Johansson P: Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 32:171–173. 2006.PubMed/NCBI View Article : Google Scholar
8	Chievitz E and Thiede T: Complications and causes of death in polycythaemia vera. Acta Med Scand. 172:513–523. 1962.PubMed/NCBI View Article : Google Scholar
9	Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, et al: Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 124:2507–2513. 2014.PubMed/NCBI View Article : Google Scholar
10	Campbell PJ and Green AR: The myeloproliferative disorders. N Engl J Med. 355:2452–2466. 2006.PubMed/NCBI View Article : Google Scholar
11	Schafer AI: Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 107:4214–4222. 2006.PubMed/NCBI View Article : Google Scholar
12	Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP and Skoda RC: Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood. 102:1869–1871. 2003.PubMed/NCBI View Article : Google Scholar
13	Kralovics R, Guan Y and Prchal JT: Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol. 30:229–236. 2002.PubMed/NCBI View Article : Google Scholar
14	Kralovics R, Stockton DW and Prchal JT: Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 102:3793–3796. 2003.PubMed/NCBI View Article : Google Scholar
15	Levy DE and Darnell JE Jr: Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol. 3:651–662. 2002.PubMed/NCBI View Article : Google Scholar
16	Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U and Pfeffer K: Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 93:397–409. 1998.PubMed/NCBI View Article : Google Scholar
17	Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, et al: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 356:459–468. 2007.PubMed/NCBI View Article : Google Scholar
18	Scott LM: The JAK2 exon 12 mutations: A comprehensive review. Am J Hematol. 86:668–676. 2011.PubMed/NCBI View Article : Google Scholar
19	Ferguson JE II, Ueland K and Aronson WJ: Polycythemia rubra vera and pregnancy. Obstet Gynecol. 62 (Suppl 3):16S–20S. 1983.PubMed/NCBI
20	Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, et al: Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 29:761–770. 2011.PubMed/NCBI View Article : Google Scholar
21	Harrison C: Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol. 129:293–306. 2005.PubMed/NCBI View Article : Google Scholar
22	Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C and Barbui T: European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 350:114–124. 2004.PubMed/NCBI View Article : Google Scholar
23	Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A and Tefferi A: The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion. Blood Cancer J. 8(15)2018.PubMed/NCBI View Article : Google Scholar
24	Bohîlţea RE, Cîrstoiu MM, Ionescu CA, Niculescu-Mizil E, Vlădăreanu AM, Voican I, Dimitriu M and Turcan N: Primary myelofibrosis and pregnancy outcomes after low molecular-weight heparin administration: A case report and literature review. Medicine (Baltimore). 96(e8735)2017.PubMed/NCBI View Article : Google Scholar
25	Thiele J, Kvasnicka HM and Diehl V: Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol. 113:213–219. 2005.PubMed/NCBI View Article : Google Scholar
26	Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405. 2016.PubMed/NCBI View Article : Google Scholar
27	Beauverd Y, Radia D, Cargo C, Knapper S, Drummond M, Pillai A, Harrison C and Robinson S: Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: Outcome and safety. A case series. Haematologica. 101:e182–e184. 2016.PubMed/NCBI View Article : Google Scholar
28	Finazzi G and Barbui T: How I treat patients with polycythemia vera. Blood. 109:5104–5111. 2007.PubMed/NCBI View Article : Google Scholar
29	Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD and Wasserman LR: From efficacy to safety: A polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 34:17–23. 1997.PubMed/NCBI
30	Bertozzi I, Rumi E, Cavalloni C, Cazzola M, Fabris F and Randi ML: Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera. Am J Hematol. 93:E234–E235. 2018.PubMed/NCBI View Article : Google Scholar
31	Yazdani Brojeni P, Matok I, Garcia Bournissen F and Koren G: A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 33:265–268. 2012.PubMed/NCBI View Article : Google Scholar
32	Bohiltea RE, Cirstoiu MM, Turcan N, Stoian AP, Zugravu CA, Munteanu O, Arsene LV, Oana B, Neacsu A and Furtunescu F: Inherited thrombophilia is significantly associated with severe preeclampsia. Exp Ther Med. 21:261–267. 2021.PubMed/NCBI View Article : Google Scholar
33	Grigoriu C, Anca AF, Grigoras M, Cezar C, Lungu A and Horhoianu V: Premature birth and systemic inflammatory response syndrome. Gineco Ro. 4:80–83. 2008.